AAP
SAGE

Arax Advisory Partners’s Sage Therapeutics SAGE Stock Holding History

Arax Advisory Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-97
Closed -$701 – 2700
2024
Q3 		$701 Hold
97
– – ﹤0.01% 2345
2024
Q2 		$1.05K Buy
+97
New +$1.24K ﹤0.01% 2161

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Arax Advisory Partners's SAGE Position: Q4 2024 in Review

Arax Advisory Partners sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 97 shares — an estimated $701 sold.

Arax Advisory Partners first reported a position in SAGE in Q2 2024 and held it in 2 quarters. The position peaked at $1.05K in Q2 2024. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Arax Advisory Partners reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 97 Sage Therapeutics shares in Q4 2024, an estimated $701.
  • Arax Advisory Partners first reported a position in Sage Therapeutics in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Sage Therapeutics position peaked at $1.05K in Q2 2024.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.